Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 12;22(1):541.
doi: 10.1186/s12887-022-03562-1.

Implementation of a provider-focused intervention for maximizing human papillomavirus (HPV) vaccine uptake in young cancer survivors receiving follow-up care in pediatric oncology practices: protocol for a cluster-randomized trial of the HPV PROTECT intervention

Wendy Landier  1   2 , Smita Bhatia  3   4 , Joshua S Richman  3 , Paula D Campos Gonzalez  3 , Brooke Cherven  5 , Veronica Chollette  6 , Jamie Aye  4 , Sharon M Castellino  5 , Maria M Gramatges  7 , Susan Lindemulder  8 , Thomas B Russell  9 , Lucie M Turcotte  10 , Graham A Colditz  11 , Melissa B Gilkey  12 , James L Klosky  5
Affiliations

Implementation of a provider-focused intervention for maximizing human papillomavirus (HPV) vaccine uptake in young cancer survivors receiving follow-up care in pediatric oncology practices: protocol for a cluster-randomized trial of the HPV PROTECT intervention

Wendy Landier et al. BMC Pediatr. .

Abstract

Background: Childhood cancer survivors are at high risk for developing new cancers (such as cervical and anal cancer) caused by persistent infection with the human papillomavirus (HPV). HPV vaccination is effective in preventing the infections that lead to these cancers, but HPV vaccine uptake is low among young cancer survivors. Lack of a healthcare provider recommendation is the most common reason that cancer survivors fail to initiate the HPV vaccine. Strategies that are most successful in increasing HPV vaccine uptake in the general population focus on enhancing healthcare provider skills to effectively recommend the vaccine, and reducing barriers faced by the young people and their parents in receiving the vaccine. This study will evaluate the effectiveness and implementation of an evidence-based healthcare provider-focused intervention (HPV PROTECT) adapted for use in pediatric oncology clinics, to increase HPV vaccine uptake among cancer survivors 9 to 17 years of age.

Methods: This study uses a hybrid type 1 effectiveness-implementation approach. We will test the effectiveness of the HPV PROTECT intervention using a stepped-wedge cluster-randomized trial across a multi-state sample of pediatric oncology clinics. We will evaluate implementation (provider perspectives regarding intervention feasibility, acceptability and appropriateness in the pediatric oncology setting, provider fidelity to intervention components and change in provider HPV vaccine-related knowledge and practices [e.g., providing vaccine recommendations, identifying and reducing barriers to vaccination]) using a mixed methods approach.

Discussion: This multisite trial will address important gaps in knowledge relevant to the prevention of HPV-related malignancies in young cancer survivors by testing the effectiveness of an evidence-based provider-directed intervention, adapted for the pediatric oncology setting, to increase HPV vaccine initiation in young cancer survivors receiving care in pediatric oncology clinics, and by procuring information regarding intervention delivery to inform future implementation efforts. If proven effective, HPV PROTECT will be readily disseminable for testing in the larger pediatric oncology community to increase HPV vaccine uptake in cancer survivors, facilitating protection against HPV-related morbidities for this vulnerable population.

Trial registration: ClinicalTrials.gov Identifier: NCT04469569, prospectively registered on July 14, 2020.

Keywords: Childhood cancer survivors; Cluster-randomized trial; Human papillomavirus; Vaccination rates.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
HPV PROTECT intervention
Fig. 2
Fig. 2
Hybrid type 1 effectiveness-implementation trial design
Fig. 3
Fig. 3
Stepped-wedge cluster-randomized trial design
Fig. 4
Fig. 4
Study schema
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Ojha RP, Jackson BE, Tota JE, Offutt-Powell TN, Hudson MM, Gurney JG. Younger age distribution of cervical cancer incidence among survivors of pediatric and young adult cancers. Gynecol Oncol. 2014;134(2):309–313. doi: 10.1016/j.ygyno.2014.05.011. - DOI - PubMed
    1. Ojha RP, Tota JE, Offutt-Powell TN, Klosky JL, Minniear TD, Jackson BE, Gurney JG. Human papillomavirus-associated subsequent malignancies among long-term survivors of pediatric and young adult cancers. PLoS ONE. 2013;8(8):e70349. doi: 10.1371/journal.pone.0070349. - DOI - PMC - PubMed
    1. Bailey HH, Chuang LT, duPont NC, Eng C, Foxhall LE, Merrill JK, Wollins DS, Blanke CD. American Society of Clinical Oncology Statement: Human Papillomavirus Vaccination for Cancer Prevention. J Clin Oncol. 2016;34(15):1803–1812. doi: 10.1200/JCO.2016.67.2014. - DOI - PubMed
    1. Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, Moreira ED, Jr, Ngan Y, Petersen LK, Lazcano-Ponce E, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711–723. doi: 10.1056/NEJMoa1405044. - DOI - PubMed
    1. Castellsague X, Giuliano AR, Goldstone S, Guevara A, Mogensen O, Palefsky JM, Group T, Shields C, Liu K, Maansson R, et al. Immunogenicity and safety of the 9-valent HPV vaccine in men. Vaccine. 2015;33(48):6892–6901. doi: 10.1016/j.vaccine.2015.06.088. - DOI - PubMed

Publication types

Substances

Associated data